Article ID Journal Published Year Pages File Type
5912657 Multiple Sclerosis and Related Disorders 2015 4 Pages PDF
Abstract

•We report a patient with severe hepatotoxicity after second infusion of natalizumab.•There are at least 12 case reports of severe liver damage attributed to Natalizumab exposure. Including one recently published fatal case.•Four of the 12 cases of natalizumab-induced liver injury were associated with features of autoimmune hepatitis.

Natalizumab is an α4-integrin monoclonal antibody used for treatment of relapsing multiple sclerosis (MS). At least and nearly 30 cases of liver failure in natalizumab-treated patients are listed in the post-marketing FDA adverse event reporting system (FAERS) and twelve patients with severe liver injury, including several after the first infusion, have been reported (Lisotti et al., 2012; Bezabeh et al., 2010; Martinez-Lapiscina et al., 2013; Michael et al., 2007; Hillen et al., 2015). Herein, we describe a case of a young woman with relapsing MS who developed acute liver injury after the second infusion of natalizumab. Liver biopsy demonstrated a mixed pattern of medication-induced injury or partially treated auto-immune hepatitis. Liver function normalized after natalizumab discontinuation and a subsequent liver biopsy showed resolution of hepatitis. The patient's MS has since been successfully treated with rituximab for over a year. We review the published cases of liver injury associated with natalizumab and those in the post-marketing FDA adverse event reporting system (FAERS).

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Genetics
Authors
, , , ,